Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Methylation-based Circulating Tumor DNA Enables Molecular Detection of Minimal Residual Disease in Long-term Responders with HER2-Positive Metastatic Breast Cancer

The Journal of Liquid Biopsy. November 2026. doi 10.1016/j.jlb.2026.100540.

The Journal of Liquid BiopsyDOI 10.1016/j.jlb.2026.100540